Zyprexa

Deutsche Bank, which acts as broker to the company, said that losing the Toprol XL patent could reduce earnings per share by 10 and 9 percent respectively in 2006 and 2007, although the outlook from 2008 would be unchanged.

Sales of Toprol XL are expected to total around $1.29 billion in 2005, or around 5 percent of the group total.

Dresdner Kleinwort Wasserstein, which believes generic manufacturers could launch their products imminently, said the setback would be taken negatively by investors.

RESULTS IN FOCUS Continued ...

© Reuters 2006.

All Rights Reserved.

1 Careers Reuters journalists are subject to the Reuters Editorial Handbook which requires fair presentation and disclosure of relevant interests.

...

Read more...